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A short term transfection technique using the chloramphenieol acetyltransferase gene as an assay system 
has been employed to examine the presence of transcriptional regulatory sequences within the variable tan- 
dem repeat (VTR) DNA sequence located ownstream of the human Ha-rasl gene. Here we find that the 
VTR sequences possess an endogenous enhancer activity of both the normal and the T24 mutant Ha-rasl 
gene. 
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1. INTRODUCTION 
The ras genes constitute an important eukaryotic 
family of genes which has attracted the interest of 
scientists in a variety of disciplines including 
cancer, cell proliferation and differentiation 
(review Ill). The ras genes have been shown to be 
activated by at least four different mechanisms in 
vivo or in vitro: (i) mutation of ras proto- 
oncogenes, i.e. in codons 12 [2-4] or 61 [5]; (ii) 
transcriptional ctivation in vitro [6-8] and in vivo 
[9-12]; (iii)gene amplification [13]; (iv)retroviral 
insertional mutagenesis [ 14,15]. Elevated levels of 
the ras encoded protein p21 have also been ob- 
served in some normal tissues [16]. Moreover, the 
fact that different ras genes are activated in dif- 
ferent tumors, i.e. Ha-ras [17] and Ki-ras [18] in 
carcinomas and N-ras in hemopoietic [19,20] or 
mesenchymal [21] tumors indicates some tissue 
specificity in the expression of these genes. 
The BamHI  fragment containing the normal or 
the T24 Ha-rasl  genes has a region of repetitive 
DNA located approx. 1.5 kb from the 3' -terminus 
of the coding sequences of the Ha-rasl  gene [22]. 
This region consists of a variable tandem repeat 
(VTR) of a 28-bp consensus sequence (fig.l). 
Previous studies have also suggested that an 
observed BamHI  restriction fragment length 
polymorphism (RFLP) arises through changes in 
the number of repeat units of this 28 bp sequence 
[23,24]. 
In the present s udy we have analyzed the VTR 
region at the 3'-end of the Ha-rasl gene for the 
presence of transcriptional enhancer activity. Our 
results demonsrate he presence of such an activity 
in this region. 
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2. MATERIALS AND METHODS 
2.1. Construct ions o f  recombinant p lasmids 
The location of the VTR sequences with respect 
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Fig. 1. Organization of the human T24 Ha-rasl gene and 
sequence of the variable tandem repeat (VTR) region. 
The coding sequences are represented by black boxes, 
the non-coding 5'-sequences by an open box and the 
VTR sequences by a crosshatched box. The direction of 
transcription is indicated by an arrow. The nucleotide 
sequence of the VTR region with the 28 bp consensus 
sequence is taken from [22]. 
to the human T24 Ha-rasl gene and its nucleotide 
sequence including the 28 bp consensus are shown 
in fig.1. The normal Ha-rasl allele contains a 
shorter VTR sequence by approx. 100 bp. The 0.8 
or 0.9 kb SphI-ClaI fragments carrying the VTR 
sequence from the normal or the T24 Ha-rasl gene 
were first recloned (by Dr J. Lang) in plasmid 
pUC18 to generate plasmids p105 and p106, 
respectively. The VTR sequences were then excised 
and recloned into the SphI-EcoRI sites of plasmid 
plC20H [25]. The VTR sequences now surrounded 
by HindlI I  sites were excised and inserted into the 
single HindlII site of each of the following 
plasmids as shown in fig.2. (i) Plasmid pB30 con- 
tains the chloramphenicol acetyltransferase (CAT) 
gene driven by the human e-globin promoter 
(fig.2a) (obtained from B. Whitelaw). (ii) Plasmid 
pCAT122A contains the CAT gene driven by the 
Ha-rasl promoter and it has been described [28] 
(fig.2b). (iii) Plasmid pB9 contains a promoterless 
CAT gene (fig.2c) (obtained from B. Whitelaw). 
2.2. DNA-mediated gene transfer and CA T assays 
Transfer and expression of recombinant 
plasmids into rat 208F fibroblast cells were carried 
out using a modification [29] of the calcium 
phosphate technique [30]. Transfected cells were 
harvested 45 h post-addition of DNA to the cells 
and the CAT assay was performed as described 
[28,311. 
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Fig.2. Schematic representation f CAT recombinant 
plasmids. (a) Structure of the recombinant plasmids 
used to assay for enhancer function. (b) Structure of the 
recombinant plasmids used to assay for enhancer 
function using the Ha-rasl promoter. (c) Structure of 
the recombinant plasmids used to assay for promoter 
function using the human E-globin promoter. Dashed 
line, pUCI2; thin line, human DNA; crosshatched box, 
VTR sequence; black box, CAT gene; hatched box, 
HSV-2 IE5 gene polyadenylation signal; open box, the 
non-coding 5'-sequences of the Ha-rasl gene; dotted 
box, human e-globin promoter [26,27]. 
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3. RESULTS 
To examine the presence of transcriptional 
regulatory sequences in the VTR sequences 
downstream of the human normal and T24 mutant 
Ha-rasl genes we investigated the ability of these 
sequences to provide enhancer or promoter activity 
using the CAT assay system. 
The structures of recombinant plasmids used to 
assay for enhancer function are shown in fig.2a. 
Plasmid pB30 contains the human e-globin pro- 
moter [26,27] in front of the CAT gene. Recom- 
binants pCAT164A and pCAT164B carry the VTR 
sequence from the normal Ha-rasl gene in the 
same or opposite orientation to the CAT gene, 
respectively. Recombinants pCAT165A and 
pCAT165B carry the VTR sequence from the T24 
mutant Ha-rasl gene in the same or opposite orien- 
tation to the CAT gene, respectively. As a positive 
control we used plasmid pLW4 which carries the 
HSV-2 gene promoter/enhancer s quences in front 
of the CAT gene [32]. Recombinant plasmids were 
introduced into rat 208F fibroblasts by the calcium 
phosphate technique. Representative results are 
shown in fig.3a and table 1. The VTR sequences 
from both the normal and T24 Ha-rasl genes 
stimulated CAT activity significantly (2.5-2.9- 
fold) in both orientations. 
To investigate whether the enhancer of the VTR 
sequence functions from a distance and on its own 
promoter hybrid CAT genes carrying the Ha-rasl 
promoter and the VTR sequences at the 3'-end of 
the CAT gene were constructed as shown in fig.2b. 
Plasmid pCAT122A contains the human Ha-rasl 
promoter in front of the CAT gene and it has been 
described [28]. Recombinant pCAT166A carries 
the VTR sequence from the normal Ha-rasl gene 
in the same orientation to the CAT gene. We did 
not obtain plasmid pCAT166B. Recombinants 
pCAT167A and pCAT167B carry the VTR se- 
quence from the T24 Ha-rasl gene in the same or 
opposite orientation to the CAT gene, respectively. 
Recombinant plasmids were assayed in 208F cells 
as above using the calcium phosphate technique. 
Representative results are shown in fig.3b and 
table 2. The VTR sequence from the normal or the 
T24 Ha-rasl genes enhanced CAT activity at low 
levels (1.7-2.0-fold). This could be due to a 
distance ffect or to the different issue specificity 
of the two distinct promoters. The e-globin pro- 
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Fig.3. Chromatograms for typical CAT assays upon 
transfection of rat 208F cells with CAT recombinants. 
Experiment using recombinants described in fig.2a (a); 
fig.2b (b); and fig.2c (c). 
moter carries ATA and CAAT boxes [27] whereas 
the Ha-rasl promoter lacks these consensus e- 
quences but is rich in GC content, a landmark of 
the promoters of house-keeping genes [28]. 
Since enhancer elements also carry some pro- 
moter function [26] we have investigated this 
possibility by employing an assay for promoter 
function. The structures of recombinant plasmids 
used are shown in fig.2c. The CAT gene lacks a 
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Table 1 
Relative values of CAT activity in rat 208F fibroblast 
cells after transfection with CAT recombinant plasmids 
Table 3 
Relative values of CAT activity in rat 208F fibroblast 
cells after transfection with CAT recombinant plasmids 
Recombinant VTR Orientation CAT activity 
plasmid a DNA relative to (AV + SD) b 
CAT 
Recombinant VTR Orientation CAT activity 
plasmid a DNA relative to (AV + SD) b 
CAT 
pB30 - - 1.0 
pLW4 - - 37 + 7.3 
pCAT164A normal same 2.5 + 0.5 
pCATI64B normal opposite 2.8 + 0.8 
pCAT165A T24 same 2.5 _ 0.7 
pCATI65B T24 opposite 2.9 + 0.9 
a See fig.2a and section 2 for plasmid constructions 
b Relative values of CAT activity of  each plasmid 
compared to the value obtained with pB30. The value 
for CAT activity after transfection of 40/~g pB30 per 
2 × 106 208F recipient cells was 5.3 × 10 -2 pmol 
acetylated//~g protein per h incubation. The average 
and SD from 4 experiments are given 
pB9 - - 1.0 
pLW4 - - 24 + 4.3 
pCATI69B normal opposite 2.9 _+ 1.6 
pCAT170A T24 normal 5.2 ___ 2.4 
pCAT170B T24 opposite 3.5 +__ 2.0 
a See fig.2c and section 2 for plasmid constructions 
b Relative values of CAT activity of each plasmid 
compared to the value obtained with pB9. The value 
for CAT activity after transfection of 40/zg pB9 per 
2 x 106 208F recipient cells was 3.0 × 10 -2 pmol 
acetylated//zg protein per h incubation. The average 
and SD from 3 experiments are given 
Table 2 
Relative values of CAT activity in rat 208F fibroblast 
ceils after transfection with CAT recombinant plasmids 
Recombinant VTR Orientation CAT activity 
plasmid a DNA relative to (AV +_ SD) b 
CAT 
pCAT122A - - 1.0 
pLW4 - - 29 ___ 5.3 
pCAT166A normal opposite 2.0 + 0.6 
pCAT167A T24 opposite 1.8 ___ 0.4 
pCATI67B T24 same 1.7 +_ 0.5 
a See fig.2b and section 2 for plasmid constructions 
b Relative values of CAT activity of each plasmid 
compared to the value obtained with pCATI22A. The 
value for CAT activity after transfection of 40/zg 
pCAT122A per 2 x 106 208F recipient cells was 7.1 x 
10 -2 pmol acetylated//zg protein per h incubation. The 
average and SD from 3 experiments are given 
promoter  in p lasmid pB9. Recombinant  
pCAT169B carries the VTR sequence f rom the 
normal  Ha-rasl gene in the opposite or ientat ion to 
the CAT gene. We did not obta in p lasmid 
pCAT169A.  Recombinants  pCAT170A and 
pCAT170B carry the VTR sequence f rom the T24 
Ha-rasl gene in the same or opposite or ientat ion to 
the CAT gene, respectively. Recombinant  plasmids 
were assayed in 208F cells as above. Representative 
results are shown in fig.3c and table 3. The VTR 
sequences f rom both the normal  and the T24 Ha-  
rasl genes st imulated CAT activity signif icantly in 
both or ientat ions (2.9-5.2- fo ld) .  However,  the 
VTR from the T24 mutant  Ha-rasl gene in the 
same or ientat ion (pCAT170A) as the CAT gene  
gave consistently higher (5.2-fold) as compared to 
the opposite or ientat ion (pCAT170B) (3.5-fold) 
CAT  activity. The reason for this is not known but 
is being investigated. 
4. D ISCUSSION 
In the present study we have analyzed the 
transcr ipt ional  regulatory functions of  the VTR se- 
quence located downstream of the human Ha-rasl 
gene. Using a short term transfect ion technique 
and the CAT assay system we have found 
transcr ipt ional  enhancer activity in this sequence. 
Consistent with our f indings are the results ob- 
ta ined by Seeburg et al. [33]. These authors have 
found that sequences containing the variable 
tandem repeat facil itate the expression of  ras p21 
in in vitro cell t ransformat ion studies. Moreover,  it 
has been reported (although no data were 
presented) that the t ransforming activity of  EJ  Ha-  
rasl DNA lacking the VTR region was 5-10- fo ld  
44 
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lower than that of the original DNA and that the 
ras p21 gene product was also reduced [23]. 
It has been suggested that variation in the size of 
the VTR region may alter expression or control of 
the Ha-rasl gene which may in turn predispose cer- 
tain cell types to malignancy [23]. The observation 
that several human tumors contain elevated levels 
of Ha-ras transcripts [8-11] taken together with 
the findings that some tumorigenic eils, i.e. EJ 
cells have a longer VTR sequence [22] is consistent 
with this hypothesis. 
Transcriptional enhancers have been usually 
found at the 5'-end or within the gene (review 
[34]). However, an enhancer element at the 3 '-end 
of the Ha-rasl gene described in this study may not 
be unique to this gene. A tissue-specific enhancer 
located at the 3' -end of the chicken adult ~'-globin 
gene has also been reported [35]. 
The consensus sequence GXTGTGGAVAAA has 
been found in many transcriptional enhancers [34]. 
This sequence when compared to the sequence con- 
tained between the SphI and ClaI sites including 
the 28-bp consensus equence of the VTR region 
(fig.l) shows no sequence homology. However, 
others have described a separate consensus e- 
quence for the enhancer found in an im- 
munoglobulin gene [36]. Moreover, studies on the 
polyomavirus enhancer sequence suggest hat an 
enhancer may comprise several types of sequence 
domain [37]. 
Our findings raise the question whether the in- 
itiation, promotion, progression and maintenance 
of some tumors depend on overexpression f the 
Ha-rasl gene. This could be the result of 
amplification, tissue specificity or mutations in the 
VTR sequence. Some of these hypotheses may be 
testable in the near future. 
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